Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex vs Lucentis in BRVO
NCT01427751Phase 4Completed
- Sponsor
- Allergan
- Start
- Oct 2011
- Primary completion
- Nov 2014
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 6
01
Overview
A Phase 4 trial of ozurdex in macular edema, branch retinal vein occlusion (BRVO), sponsored by Allergan. Started Oct 2011; status: completed.
02
Drugs
ozurdex
03
Conditions
macular edemabranch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT01427751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427751.